ESR1 and cancer: The present study was conducted to investigate the CYP’s action as an endocrine disrupter by examining its xenoestrogenic effects on cancer cell proliferation, EMT, and metastasis by using an ER-dependent and estrogen-responsive Ishikawa endometrial cancer cell line, which is a well-differentiated adenocarcinoma cell line derived from the human endometrial epithelium that expresses functional ER [27].